已收盘 01-30 16:00:00 美东时间
-7.710
-2.39%
今日重点评级关注:瑞穗:维持Syndax制药"跑赢大市"评级,目标价从410美元升至600美元;HC Wainwright & Co.:维持60 Degrees Pharmaceuticals, Inc."买入"评级,目标价从6美元升至24美元
01-28 10:59
今日重点评级关注:Oppenheimer:维持Pelthos Therapeutics"跑赢大市"评级,目标价从57美元升至60美元;Small Cap Consumer Research:维持Lands' End"买入"评级,目标价从20美元升至45美元
01-27 10:02
Morgan Stanley analyst James Faucette upgrades Corpay (NYSE:CPAY) from Equal-Weight to Overweight and raises the price target from $322 to $379.
01-26 20:14
今日重点评级关注:HC Wainwright & Co.:维持Enlivex Therapeutics"买入"评级,目标价从7美元升至13美元;BTIG:维持Oruka Therapeutics"买入"评级,目标价从63美元升至73美元
01-13 10:18
In the latest quarter, 5 analysts provided ratings for Corpay (NYSE:CPAY), show...
01-13 05:00
Oppenheimer analyst Rayna Kumar maintains Corpay (NYSE:CPAY) with a Outperform and lowers the price target from $380 to $369.
01-13 01:35
Transaction values Corpay Cross-Border Business at approximately $13 billionCorpay, Inc. (NYSE:CPAY), the corporate payments company, today announced that it has completed Mastercard's (NYSE:MA) $300 million minority
2025-12-09 05:09
今日重点评级关注:Stifel:维持X4 Pharmaceuticals"买入"评级,目标价从7.5美元升至10美元;花旗:维持UP Fintech Holding"买入"评级,目标价从17.4美元升至17.5美元
2025-12-08 08:34
Oppenheimer analyst Rayna Kumar upgrades Corpay (NYSE:CPAY) from Perform to Outperform and announces $380 price target.
2025-12-06 01:47